<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="366207">
  <stage>Registered</stage>
  <submitdate>22/04/2014</submitdate>
  <approvaldate>1/05/2014</approvaldate>
  <actrnumber>ACTRN12614000451606</actrnumber>
  <trial_identification>
    <studytitle> An evaluation of the drug interaction potential of modafinil in healthy volunteers, using a cocktail approach</studytitle>
    <scientifictitle>An investigation of the proportional change in area under the concentration-time curves for five orally administered CYP P450 probes (caffeine, losartan, omeprazole, dextromethorphan, midazolam) when administered with and without single-dose and steady-state oral modafinil, in twelve healthy adult volunteers.</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>MODDI-14</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Drug-drug interactions</healthcondition>
    <conditioncode>
      <conditioncode1>Other</conditioncode1>
      <conditioncode2>Research that is not of generic health relevance and not applicable to specific health categories listed above</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Simultaenous administration of single doses of five drugs (caffeine 100mg, losartan 25mg, omperazole 20mg, dextromethorphan 30mg, midazolam 2mg) on three occasions on study days 0,1 and 7. These drugs will be administered orally (as tablets - caffeine, losartan, omeprazole; as solutions diluted in water - midazolam, dextromethorphan) with water. Administration of modafinil 200mg daily for seven days on study Days 1 to 7. The modafinil will be given as tablets with water. A single modafinil plasma concentration will be measured post-dose on Day 7 to monitor adherence and to ensure steady-state has been achieved.</interventions>
    <comparator>Not Applicable</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Treatment: Drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Probe drug concentrations-time profile following administration of the drug cocktail. Plasma drug concentrations of probe drugs will be determined by LC-MS.</outcome>
      <timepoint>Sampling to occur at 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10 and 24 hours post administration of the cocktail of probe drugs.</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Clinical assessment and monitoring of heart rate and blood pressure will be used to monitor safety on the days when the five drug combination is given.</outcome>
      <timepoint>Monitoring of adverse effects will be undertaken across the full duration of the study (8 days)</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>nil</outcome>
      <timepoint>nil</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Healthy
Aged 18 - 40</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>40</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Males</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>taking medications
significant health conditions
unable to comply with study requirements</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Diagnosis</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>28/11/2014</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate>31/07/2015</anticipatedenddate>
    <actualenddate />
    <samplesize>12</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>SA</recruitmentstate>
    <hospital>Flinders Medical Centre - Bedford Park</hospital>
    <postcode>5042 - Bedford Park</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>Flinders University</primarysponsorname>
    <primarysponsoraddress>Flinders Drive
Bedford Park
South Australia 5042</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>University</fundingtype>
      <fundingname>Flinders University</fundingname>
      <fundingaddress>Flinders Drive
Bedford Park
South Australia 5042</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>To assess the capacity of a vigilance promoting agent (modafinil) to perpetrate metabolic drug interactions that may lead to adverse effects.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Southern Adelaide Clinical Human Research Ethics Committee</ethicname>
      <ethicaddress>Flinders Medical Center
Flinders Drive
Bedford Park
South Australia 5042</ethicaddress>
      <ethicapprovaldate>16/07/2014</ethicapprovaldate>
      <hrec>HREC/14/SAC/203</hrec>
      <ethicsubmitdate>30/05/2014</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Andrew Rowland</name>
      <address>Department of Clinical Pharmacology 
Flinders Medical Centre 
Flinders Drive
Bedford Park 
South Australia 5042</address>
      <phone>+61 8 8204 7546</phone>
      <fax />
      <email>andrew.rowland@flinders.edu.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Andrew Rowland</name>
      <address>Department of Clinical Pharmacology 
Flinders Medical Centre 
Flinders Drive
Bedford Park 
South Australia 5042</address>
      <phone>+61 8 8204 7546</phone>
      <fax />
      <email>andrew.rowland@flinders.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Andrew Rowland</name>
      <address>Department of Clinical Pharmacology 
Flinders Medical Centre 
Flinders Drive
Bedford Park 
South Australia 5042</address>
      <phone>+61 8 8204 7546</phone>
      <fax />
      <email>andrew.rowland@flinders.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>